Cargando…
Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in Western industrialized countries and may progress to liver injury. Cortisol is thought to play a role in the pathogenesis of NAFLD, and cortisol modulation has shown efficacy in preclinical models. However, pub...
Autores principales: | Parker, John C., Moraitis, Andreas G., Belanoff, Joseph K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Clinical Endocrinology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784715/ https://www.ncbi.nlm.nih.gov/pubmed/35097198 http://dx.doi.org/10.1016/j.aace.2021.07.001 |
Ejemplares similares
-
ODP322 Impact of Mifepristone on Liver Function and Resolution of Liver Steatosis in Patients with Cushing Syndrome – A Case Study
por: East, Honey E, et al.
Publicado: (2022) -
FRI183 Phase 4 Study Of Hypercortisolism In Patients With Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence And Treatment With Mifepristone
por: Frias, Juan Pablo, et al.
Publicado: (2023) -
Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016) -
SUN-383 Sustained Clinical Improvement after Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
por: Anderson, Robin, et al.
Publicado: (2019) -
Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma
por: Ragucci, Enzo, et al.
Publicado: (2017)